RedFlag Index™ · #6 of 10 · NYSE: LLY

Eli Lilly and Company: enforcement record and regulatory exposure

Eli Lilly and Company scores 59 out of 100 on the RedFlag Index™ (November 2026), ranking #6 of ten tracked companies, with 8 documented cases of which 5 remain open.

Eli Lilly has paid about $3.0 billion in tracked penalties since 2000.

September 2026: Florida sued Eli Lilly, alleging it set Humalog's list price at about $280 a vial while returning about $210 to PBMs as rebates. The suit alleges uninsured patients pay the full list price. The case is unresolved.

The same complaint says Eli Lilly, Novo Nordisk, and Sanofi supply more than 90% of the world's insulin.

2009: Eli Lilly paid $1.415 billion over Zyprexa, including a $515 million criminal fine.

2005: Eli Lilly paid $36 million over Evista, including a $6 million criminal fine.

DateMatterAmountStatus
October 26, 2026Missouri AG cease-and-desist over 340B claims-data conditionOpen
October 9, 2026Pennsylvania AG insulin pricing suitOpen
September 2026Florida AG Humalog pricing suitOpen
January 15, 2026Missouri AG insulin pricing suitOpen
January 7, 2026Oregon AG insulin pricing suitOpen
August 2025Texas AG kickback suit over nurse and reimbursement supportOpen
October 2024Texas AG insulin pricing suitOpen
February 7, 2024Minnesota insulin pricing settlement ($35 cap, no penalty)No penaltyResolved
2023Medicaid rebate FCA judgment (Streck); certiorari denied May 2026$183.7mJudgment
January 2009Zyprexa resolution incl. $515m criminal fine$1.42bnResolved
December 2005Evista off-label resolution incl. $6m criminal fine$36mResolved

Government enforcement only. Greyed rows are more than ten years old and excluded from scoring under the temporal decay rule.

  1. 340B Program

    Missouri orders Eli Lilly to drop 340B claims-data condition after hospital cut-off

    Missouri Attorney General Catherine Hanaway sent Eli Lilly a cease-and-desist letter alleging its requirement that 340B hospitals hand over claims data violates state consumer protection law. Lilly had cut University of Missouri Health Care off from 340B pricing in July.

  2. Drug Pricing

    Pennsylvania sues the three largest insulin makers and PBMs over alleged pricing scheme

    Pennsylvania Attorney General Dave Sunday sued Eli Lilly, Novo Nordisk, Sanofi, Express Scripts, CVS Caremark and OptumRx under the state's consumer protection law. Because Pennsylvania has no general antitrust statute, the case relies on deception claims rather than price-fixing law.

  3. State Enforcement

    Texas sues Sanofi over free nurse and support services kickback allegations

    Texas Attorney General Ken Paxton has sued Sanofi-Aventis U.S. LLC, alleging that its Free Nurse Program and Support Services Program amounted to in-kind kickbacks to providers under the Texas Health Care Program Fraud Prevention Act. The state seeks more than $1 million in monetary relief, including civil penalties, and an injunction.

  4. PBM Rebates

    Missouri sues 19 PBMs and insulin makers over alleged pricing scheme

    Missouri Attorney General Catherine Hanaway has sued 19 pharmacy benefit manager and drug manufacturer defendants, alleging a scheme to inflate insulin prices in violation of the Missouri Merchandising Practices Act. The state seeks injunctive relief, restitution, damages and disgorgement.

  5. Drug Pricing

    Oregon seeks $900 million from insulin makers and PBMs over pricing

    Oregon Attorney General Dan Rayfield has filed a $900 million lawsuit against Novo Nordisk, Sanofi, Eli Lilly, Express Scripts, CVS Caremark and Optum, alleging a coordinated scheme to inflate insulin and diabetes drug prices. The 173-page complaint was filed in Multnomah County Circuit Court.

  6. Drug Pricing

    Eli Lilly settles with Minnesota to cap insulin at $35 a month for uninsured residents

    Minnesota Attorney General Keith Ellison announced a settlement with Eli Lilly under which Lilly agreed to cap insulin prices at $35 per month for uninsured Minnesotans and donate insulin to free clinics serving low-income patients. No liability was admitted. The settlement built on Minnesota's 2020 Alec Smith Insulin Affordability Act.